GlassScriptPhysician profile
Perminder S Sanghera
NPI 1417028523
$2,449.58
in general payments reported to CMS, 2019-2025
31 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $584 · 2020: $463 · 2021: $243 · 2022: $392 · 2023: $281 · 2024: $192 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $767.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $333.42 | 2019-2025 | Krystexxa, Repatha |
| Boston Scientific Corporation | $290.18 | 2019-2025 | General - Therapies |
| Medtronic, INC. | $265.95 | 2023-2024 | Corevalve Evolut R, Micra |
| Novartis Pharmaceuticals Corporation | $185.20 | 2020-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.64 | 2021-2024 | Synjardy, Jardiance, Tradjenta |
| Biotronik INC. | $147.65 | 2022 | |
| Pfizer INC. | $132.65 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $108.53 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $82.50 | 2019-2024 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $82.19 | 2019-2021 | |
| Abbott Laboratories | $70.35 | 2019-2025 | Gallant, Eterna |
| Akebia Therapeutics INC | $57.05 | 2020 | |
| Philips North America LLC | $47.30 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $47.15 | 2019-2021 | |
| Allergan, INC. | $45.80 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $40.42 | 2023 | Inspire |
| Lilly USA, LLC | $39.36 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $33.92 | 2025 | Zenpep |
| Esperion Therapeutics, INC. | $32.31 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.53 | 2019-2021 | |
| Eisai INC. | $27.40 | 2020-2021 | |
| Medtronic USA, INC. | $25.10 | 2019 | |
| Abbvie INC. | $24.88 | 2019 | |
| Glaxosmithkline, LLC. | $22.32 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $21.67 | 2022 | |
| Novo Nordisk INC | $20.91 | 2021 | |
| Janssen Pharmaceuticals, INC | $20.54 | 2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $20.39 | 2024 | |
| Nalu Medical, INC. | $18.67 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.96 | 2022 | |
| Qiagen, LLC | $12.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Perminder Sanghera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.